Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

[1]  B. Jasani,et al.  Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. , 2009, Vaccine.

[2]  B. Neyns,et al.  Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients , 2009, Clinical Cancer Research.

[3]  J. Aerts,et al.  Attenuated Expression of A20 Markedly Increases the Efficacy of Double-Stranded RNA-Activated Dendritic Cells As an Anti-Cancer Vaccine1 , 2009, The Journal of Immunology.

[4]  R. Tyagi,et al.  RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells - Retracted , 2009, Expert review of anticancer therapy.

[5]  C. Figdor,et al.  Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells , 2009, Cancer Immunology, Immunotherapy.

[6]  B. Walker,et al.  Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. , 2008, Cancer research.

[7]  P. Coulie,et al.  About human tumor antigens to be used in immunotherapy. , 2008, Seminars in immunology.

[8]  M. Neller,et al.  Antigens for cancer immunotherapy. , 2008, Seminars in immunology.

[9]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[10]  I. Svane,et al.  Studies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic Potential , 2008, Molecular biotechnology.

[11]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  C. Meijer,et al.  Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. , 2008, Clinical immunology.

[13]  E. Tartour,et al.  Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. , 2008, Cancer research.

[14]  C. Figdor,et al.  Dendritic cell vaccines in melanoma: from promise to proof? , 2008, Critical reviews in oncology/hematology.

[15]  C. Figdor,et al.  Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration , 2008, Cancer Immunology, Immunotherapy.

[16]  B. Neyns,et al.  Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells1 , 2008, The Journal of Immunology.

[17]  D. Hart,et al.  Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells , 2008, Gene Therapy.

[18]  C. Hofmann,et al.  Dendritic cell vaccination and other strategies to tip the balance of the immune system , 2008, Cancer Immunology, Immunotherapy.

[19]  H. Schild,et al.  Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals1 , 2008, The Journal of Immunology.

[20]  M. Lenjou,et al.  Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+ regulatory T cells , 2007, Journal of cellular and molecular medicine.

[21]  I. Svane,et al.  Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters , 2008, Cancer Immunology, Immunotherapy.

[22]  G. Schuler,et al.  Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes , 2008, Cancer Immunology, Immunotherapy.

[23]  C A Nicolette,et al.  Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. , 2007, Vaccine.

[24]  G. Schuler,et al.  Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection , 2007, Journal of immunotherapy.

[25]  J. Aerts,et al.  Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells , 2007, Journal of leukocyte biology.

[26]  J. Villadangos,et al.  Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo , 2007, Nature Reviews Immunology.

[27]  P. Greenberg,et al.  Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. , 2007, Blood.

[28]  M. Bevan,et al.  Requirements for CD8 T-cell priming, memory generation and maintenance. , 2007, Current opinion in immunology.

[29]  B. Neyns,et al.  Current approaches in dendritic cell generation and future implications for cancer immunotherapy , 2007, Cancer Immunology, Immunotherapy.

[30]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[31]  J. Bergman,et al.  An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. , 2007, Journal of immunological methods.

[32]  J. Aerts,et al.  CD83 expression on dendritic cells and T cells: Correlation with effective immune responses , 2007, European journal of immunology.

[33]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[35]  C. Meijer,et al.  Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells , 2007, Gene Therapy.

[36]  T. Scheenen,et al.  Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines , 2006, International journal of cancer.

[37]  S. Aamdal,et al.  T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells , 2007, Cancer Immunology, Immunotherapy.

[38]  E. Kremmer,et al.  Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 , 2007, Journal of Translational Medicine.

[39]  U. Şahin,et al.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. , 2006, Blood.

[40]  S. Aamdal,et al.  Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA , 2006, Cancer Gene Therapy.

[41]  R. Steinman,et al.  Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. , 2006, Blood.

[42]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[43]  A. Dietz,et al.  Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma , 2006, Journal of Translational Medicine.

[44]  J. Yewdell,et al.  The DRiP hypothesis decennial: support, controversy, refinement and extension. , 2006, Trends in immunology.

[45]  J. Aerts,et al.  Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA , 2006, Gene Therapy.

[46]  Laurie Lamoreaux,et al.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. , 2006, Journal of immunological methods.

[47]  C. Sousa,et al.  Dendritic cells in a mature age , 2006, Nature Reviews Immunology.

[48]  G. Gaudernack,et al.  Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[49]  L Edler,et al.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Pichon,et al.  mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. , 2006, Biochemical and biophysical research communications.

[51]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[52]  L. Nielsen,et al.  Generation and Maturation of Dendritic Cells for Clinical Application Under Serum-Free Conditions , 2005, Journal of immunotherapy.

[53]  H. Stauss,et al.  Antigen-specific cellular immunotherapy of leukemia , 2005, Leukemia.

[54]  Arend Heerschap,et al.  Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy , 2005, Nature Biotechnology.

[55]  S. Aamdal,et al.  Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients , 2005, British Journal of Cancer.

[56]  A. Enk.  Dendritic cells in tolerance induction. , 2005, Immunology letters.

[57]  J. Borst,et al.  CD27 and CD70 in T cell and B cell activation. , 2005, Current opinion in immunology.

[58]  F. Brasseur,et al.  Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.

[59]  C. Figdor,et al.  Migration of dendritic cell based cancer vaccines: in vivo veritas? , 2005, Current opinion in immunology.

[60]  A. M. Neale,et al.  Results of a phase I study utilizing monocyte‐derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma , 2005, Cancer.

[61]  Donna Niedzwiecki,et al.  Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.

[62]  G. Schuler,et al.  Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation1 , 2005, The Journal of Immunology.

[63]  D. V. van Bockstaele,et al.  Messenger Rna Electroporation: an Efficient Tool in Immunotherapy and Stem Cell Research , 2022 .

[64]  B. Neyns,et al.  Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells , 2004, The journal of gene medicine.

[65]  Gabrielle T Belz,et al.  Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.

[66]  M. Dullaers,et al.  Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[68]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[69]  S. Pascolo.  Messenger RNA-based vaccines , 2004, Expert opinion on biological therapy.

[70]  A. Moretti,et al.  Evaluation of in vivo labelled dendritic cell migration in cancer patients , 2004, Journal of Translational Medicine.

[71]  A. M. Neale,et al.  Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. , 2004, Neuro-oncology.

[72]  E. Gilboa,et al.  Induction of Human Dendritic Cell Maturation Using Transfection with RNA Encoding a Dominant Positive Toll-Like Receptor 41 , 2004, The Journal of Immunology.

[73]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[74]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[75]  P. Ponsaerts,et al.  Cancer immunotherapy using RNA‐loaded dendritic cells , 2003, Clinical and experimental immunology.

[76]  E. Gilboa,et al.  Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation 1 , 2003, The Journal of Immunology.

[77]  G. Kvalheim,et al.  A Protocol for Generation of Clinical Grade mRNA‐Transfected Monocyte‐Derived Dendritic Cells for Cancer Vaccines , 2003, Scandinavian journal of immunology.

[78]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  V. Engelhard,et al.  Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, The Journal of experimental medicine.

[80]  M. R̆ic̆icová,et al.  Comparative analyses of Saccharomyces cerevisiae RNAs using Agilent RNA 6000 Nano Assay and agarose gel electrophoresis. , 2003, FEMS yeast research.

[81]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[82]  C. Heirman,et al.  Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells , 2003, Cancer Gene Therapy.

[83]  C. Heirman,et al.  Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. , 2003, Cancer research.

[84]  Matteo Bellone,et al.  Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. , 2003, Cancer research.

[85]  P. Brossart,et al.  Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes1 , 2003, The Journal of Immunology.

[86]  Steven A. Rosenberg,et al.  Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1 , 2003, The Journal of Immunology.

[87]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[88]  A. Ballestrero,et al.  Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer , 2003, Cancer Gene Therapy.

[89]  P. Brossart,et al.  Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes , 2003, Gene Therapy.

[90]  E. Gilboa,et al.  Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA , 2003, Cancer investigation.

[91]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[92]  S. Ferrone,et al.  HLA class I antigen loss, tumor immune escape and immune selection. , 2002, Vaccine.

[93]  Gerold Schuler,et al.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? , 2002, Trends in immunology.

[94]  C. van Broeckhoven,et al.  Messenger RNA Electroporation of Human Monocytes, Followed by Rapid In Vitro Differentiation, Leads to Highly Stimulatory Antigen-Loaded Mature Dendritic Cells1 , 2002, The Journal of Immunology.

[95]  R. Förster,et al.  Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. , 2002, Blood.

[96]  C. Broeckhoven,et al.  mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation , 2002, Leukemia.

[97]  Kris Thielemans,et al.  Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.

[98]  D. Tyler,et al.  Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. , 2002, The Journal of surgical research.

[99]  E. Gilboa,et al.  Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells , 2002, Annals of surgery.

[100]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[101]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  S. Saebøe-Larssen,et al.  mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). , 2002, Journal of immunological methods.

[103]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[104]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[105]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[106]  P. Kalinski,et al.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. , 2001, Blood.

[107]  P. Dahm,et al.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. , 2001, Cancer research.

[108]  R. Zinkernagel,et al.  Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells1 , 2001, The Journal of Immunology.

[109]  Edgar G. Engleman,et al.  Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.

[110]  E. Gilboa,et al.  Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1 , 2001, The Journal of Immunology.

[111]  Wangxue Chen,et al.  Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. , 2001, Hepato-gastroenterology.

[112]  Hua Yu,et al.  Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1 , 2001, The Journal of Immunology.

[113]  R. Offringa,et al.  Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. , 2000, Cancer research.

[114]  P. Hwu,et al.  Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen‐specific T lymphocytes , 2000, European journal of immunology.

[115]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[116]  R. Crystal,et al.  Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. , 2000, Blood.

[117]  E. Gilboa,et al.  Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1 , 2000, The Journal of Immunology.

[118]  E. Gilboa,et al.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.

[119]  A. Lanzavecchia,et al.  The interplay between the duration of TCR and cytokine signaling determines T cell polarization , 1999, European journal of immunology.

[120]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[121]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[122]  L. Aarden,et al.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production , 1995, The Journal of experimental medicine.

[123]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.